NasdaqCM:MEIP

Stock Analysis Report

Executive Summary

MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer.

Snowflake

Fundamentals

Flawless balance sheet and slightly overvalued.

Share Price & News

How has MEI Pharma's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

3.6%

MEIP

3.8%

US Biotechs

2.3%

US Market


1 Year Return

-57.8%

MEIP

-10.0%

US Biotechs

5.6%

US Market

Return vs Industry: MEIP underperformed the US Biotechs industry which returned -10% over the past year.

Return vs Market: MEIP underperformed the US Market which returned 5.6% over the past year.


Shareholder returns

MEIPIndustryMarket
7 Day3.6%3.8%2.3%
30 Day-14.3%-2.8%-1.0%
90 Day-11.9%-2.6%-0.7%
1 Year-57.8%-57.8%-9.2%-10.0%7.9%5.6%
3 Year5.6%5.6%14.7%10.7%45.6%36.3%
5 Year-77.8%-77.8%2.2%-2.8%65.8%47.6%

Price Volatility Vs. Market

How volatile is MEI Pharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is MEI Pharma undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Undervalued: MEIP ($1.71) is trading below our estimate of fair value ($54.97)

Significantly Undervalued: MEIP is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: MEIP is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: MEIP is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate MEIP's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MEIP is overvalued based on its PB Ratio (2.6x) compared to the US Biotechs industry average (2.6x).


Next Steps

Future Growth

How is MEI Pharma forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

46.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MEIP is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MEIP is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MEIP is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: MEIP's revenue (52.3% per year) is forecast to grow faster than the US market (7.3% per year).

High Growth Revenue: MEIP's revenue (52.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: Insufficient data to determine if MEIP's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has MEI Pharma performed over the past 5 years?

2.8%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: MEIP is unprofitable, but has reduced losses over the past 5 years at a rate of 2.8% per year.

Accelerating Growth: Unable to compare MEIP's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MEIP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (78.4%).


Return on Equity

High ROE: MEIP has a negative Return on Equity (-35.09%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: MEIP is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: MEIP is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is MEI Pharma's financial position?


Financial Position Analysis

Short Term Liabilities: MEIP's short term assets ($82.2M) exceeds its short term liabilities ($14.3M)

Long Term Liabilities: MEIP's short term assets (82.2M) exceeds its long term liabilities (20.4M)


Debt to Equity History and Analysis

Debt Level: MEIP is debt free.

Reducing Debt: MEIP has not had any debt for past 5 years.


Balance Sheet

Inventory Level: MEIP has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if MEIP's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MEIP has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: MEIP has sufficient cash runway for 1.351440 years if free cash flow continues to reduce at historical rates of -57.2% each year.


Next Steps

Dividend

What is MEI Pharma's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage2.0%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate MEIP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate MEIP's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if MEIP's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MEIP's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MEIP's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of MEI Pharma's salary, the management and board of directors tenure and is there insider trading?

4.3yrs

Average management tenure


CEO

Dan Gold (65yo)

9.5yrs

Tenure

US$2,985,416

Compensation

Dr. Daniel P. Gold, also known as Dan, Ph.D. has been the Chief Executive Officer and President of MEI Pharma, Inc. (Alternate Name: Marshall Edwards Inc.), a subsidiary of Novogen Limited since April 26,  ...


CEO Compensation Analysis

Compensation vs. Market: Dan's total compensation ($USD2.99M) is about average for companies of similar size in the US market ($USD493.00K).

Compensation vs Earnings: Dan's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

4.3yrs

Average Tenure

59.5yo

Average Age

Experienced Management: MEIP's management team is considered experienced (4.3 years average tenure).


Board Age and Tenure

6.3yrs

Average Tenure

66yo

Average Age

Experienced Board: MEIP's board of directors are considered experienced (6.3 years average tenure).


Insider Trading

Insider Buying: MEIP insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUS$26,07509 Sep 19
Christine White
EntityIndividual
Role
Chairman of the Board
Non-Executive Chairman
Shares15,000
Max PriceUS$1.74

Ownership Breakdown


Management Team

  • Brian Drazba (58yo)

    Secretary & CFO

    • Tenure: 2.5yrs
    • Compensation: US$1.02m
  • Richard Ghalie (61yo)

    Senior Vice President of Clinical Development

    • Tenure: 3.6yrs
  • Dan Gold (65yo)

    CEO, President & Director

    • Tenure: 9.5yrs
    • Compensation: US$2.99m
  • David Urso (55yo)

    COO, Senior VP of Corporate Development & General Counsel

    • Tenure: 1.3yrs
    • Compensation: US$1.25m
  • David Walsey

    Vice President of IR & Corporate Communications

    • Tenure: 0yrs
  • Karen Potts (56yo)

    Senior Vice President of Regulatory Affairs

    • Tenure: 5yrs
  • Robert Mass (65yo)

    Chief Medical Officer

    • Tenure: 8.3yrs
    • Compensation: US$879.31k

Board Members

  • Tamar Howson (70yo)

    Non-Executive Director

    • Tenure: 0.3yrs
  • Fred Driscoll (68yo)

    Non-Executive Director

    • Tenure: 1.7yrs
    • Compensation: US$68.11k
  • Dan Gold (65yo)

    CEO, President & Director

    • Tenure: 9.5yrs
    • Compensation: US$2.99m
  • Bill Rueckert (66yo)

    Non Executive Director

    • Tenure: 8.5yrs
    • Compensation: US$148.91k
  • Nick Glover (50yo)

    Non-Executive Director

    • Tenure: 6.3yrs
    • Compensation: US$138.91k
  • Kevan Clemens (75yo)

    Non Executive Director

    • Tenure: 4.8yrs
    • Compensation: US$132.91k
  • Christine White (67yo)

    Non-Executive Chairman

    • Tenure: 3.8yrs
    • Compensation: US$157.03k
  • Tom Reynolds (60yo)

    Non-Executive Director

    • Tenure: 6.7yrs
    • Compensation: US$133.91k
  • Charles Baltic (58yo)

    Non-Executive Director

    • Tenure: 8yrs
    • Compensation: US$141.41k

Company Information

MEI Pharma, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: MEI Pharma, Inc.
  • Ticker: MEIP
  • Exchange: NasdaqCM
  • Founded: 2000
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$125.916m
  • Shares outstanding: 73.63m
  • Website: https://www.meipharma.com

Number of Employees


Location

  • MEI Pharma, Inc.
  • 3611 Valley Centre Drive
  • Suite 500
  • San Diego
  • California
  • 92130
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MEIPNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDDec 2003
MMIADB (Deutsche Boerse AG)YesCommon StockDEEURDec 2003
0JW9LSE (London Stock Exchange)YesCommon StockGBUSDDec 2003

Biography

MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. The company’s clinical drug candidate includes Pracinostat, an oral avail ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/16 23:48
End of Day Share Price2019/10/16 00:00
Earnings2019/06/30
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.